Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Krassimir Mitchev steps up as acting CMO

Interim Report Q3, 2019

Calliditas Therapeutics’ nomination committee for the AGM 2020

Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon

Positive feedback from FDA significantly benefits ongoing NefIgArd pivotal Phase 3 study

Interim Report Q2, 2019

Strategic in-licensing related to autoimmune hepatitis in the US market

Number of shares and votes in Calliditas Therapeutics

Calliditas has resolved on a directed share issue in the amount of 3.5 million shares, raising proceeds of approximately SEK 210 million

Calliditas considers a directed share issue

Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Interim Report Q1, 2019

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics’ 2018 Annual Report published

Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis

Year-end report, 2018

Calliditas Therapeutics granted orphan drug designation by the FDA for Autoimmune hepatitis

Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

© Calliditas Therapeutics AB 2019